文献速递细菌感染、耐药与抗菌药物

辅助性达托霉素治疗甲氧西林敏感金黄色葡萄球菌菌血症的随机对照试验

Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2021-01-01

在加拿大2家学术医院开展的随机双盲安慰剂对照试验,纳入接受头孢唑林或氯唑西林单药治疗的MSSA菌血症成人患者,比较加用5天达托霉素与安慰剂的疗效。

要点

  • 不推荐在标准治疗基础上常规加用达托霉素治疗MSSA菌血症。

核心结论

  • 在MSSA菌血症患者中,标准治疗基础上加用辅助达托霉素未缩短菌血症持续时间,不应常规考虑。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在加拿大蒙特利尔2家学术医院进行。
  • 筛查318例,入组115例,意向性分析纳入104例(中位年龄67岁,女性34.5%)。
  • 患者为≥18岁接受头孢唑林或氯唑西林单药治疗的MSSA菌血症患者,除标准治疗外接受5天辅助达托霉素或安慰剂。

临床怎么用

  • MSSA菌血症标准治疗为头孢唑林或氯唑西林单药,不应常规加用达托霉素辅助治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bloodstream infections (BSIs) with methicillin-susceptible Staphylococcus aureus (MSSA) are associated with significant morbidity and mortality. Our objective in this study was to determine the efficacy of synergistic treatment with daptomycin when given with either cefazolin or cloxacillin for the treatment of MSSA BSI. METHODS: A randomized, double-blind, placebo-controlled trial was performed at 2 academic hospitals in Montreal, Canada. Patients aged ≥18 years with MSSA BSI receiving either cefazolin or cloxacillin monotherapy were considered for inclusion. In addition to the standard-of-care treatment, participants received a 5-day course of adjunctive daptomycin or placebo. The primary outcome was the duration of MSSA BSI in days. RESULTS: Of 318 participants screened, 115 were enrolled and 104 were included in the intention-to-treat analysis (median age, 67 years; 34.5% female). The median duration of bacteremia was 2.04 days among patients who received daptomycin vs 1.65 days in those who received placebo (absolute difference, 0.39 days; P = .40). In a modified intention-to-treat analysis that involved participants who remained bacteremic at the time of enrollment, we found a median duration of bacteremia of 3.06 days among patients who received daptomycin vs 3.0 days in those who received placebo (absolute difference, 0.06 days; P = .77). Ninety-day mortality in the daptomycin arm was 18.9% vs 17.7% in the placebo arm (P = 1.0). CONCLUSIONS: Among patients with MSSA BSIs, the administration of adjunctive daptomycin therapy to standard-of-care treatment did not shorten the duration of bacteremia and should not be routinely considered. CLINICAL TRIALS REGISTRATION: NCT02972983.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cheng MP, Lawandi A, Butler-Laporte G, et al. Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial. Clin Infect Dis. 2021. PMID: 32667982. doi:10.1093/cid/ciaa1000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。